350 related articles for article (PubMed ID: 25859860)
1. Role of complement and complement regulatory proteins in the complications of diabetes.
Ghosh P; Sahoo R; Vaidya A; Chorev M; Halperin JA
Endocr Rev; 2015 Jun; 36(3):272-88. PubMed ID: 25859860
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.
Liu F; Sahoo R; Ge X; Wu L; Ghosh P; Qin X; Halperin JA
J Diabetes Complications; 2017 Feb; 31(2):311-317. PubMed ID: 27729184
[TBL] [Abstract][Full Text] [Related]
3. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes.
Qin X; Goldfine A; Krumrei N; Grubissich L; Acosta J; Chorev M; Hays AP; Halperin JA
Diabetes; 2004 Oct; 53(10):2653-61. PubMed ID: 15448097
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for a link between complement and the vascular complications of diabetes.
Acosta J; Hettinga J; Flückiger R; Krumrei N; Goldfine A; Angarita L; Halperin J
Proc Natl Acad Sci U S A; 2000 May; 97(10):5450-5. PubMed ID: 10805801
[TBL] [Abstract][Full Text] [Related]
5. Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice.
Wu G; Chen T; Shahsafaei A; Hu W; Bronson RT; Shi GP; Halperin JA; Aktas H; Qin X
Circulation; 2010 Mar; 121(11):1338-46. PubMed ID: 20212283
[TBL] [Abstract][Full Text] [Related]
6. The effect of glycation of CD59 on complement-mediated cytolysis.
Cheng Y; Gao M
Cell Mol Immunol; 2005 Aug; 2(4):313-7. PubMed ID: 16274631
[TBL] [Abstract][Full Text] [Related]
7. Hyperglycemia and the pathobiology of diabetic complications.
Aronson D
Adv Cardiol; 2008; 45():1-16. PubMed ID: 18230953
[TBL] [Abstract][Full Text] [Related]
8. Immunization against tumor cell surface complement-regulatory proteins.
Durrant LG; Spendlove I
Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
[TBL] [Abstract][Full Text] [Related]
9. [Membrane-attacking complexes and membrane complement inhibitors on the leukocyte surface during combined exposure with meningococcus lipopolysaccharide and complement].
Platonov AE; Vershinina IV; Serebrovskaia LV; Shepeleva GK
Biull Eksp Biol Med; 1999 Apr; 127(4):433-8. PubMed ID: 10367130
[No Abstract] [Full Text] [Related]
10. A distinctive histidine residue is essential for in vivo glycation-inactivation of human CD59 transgenically expressed in mice erythrocytes: Implications for human diabetes complications.
Sahoo R; Ghosh P; Chorev M; Halperin JA
Am J Hematol; 2017 Nov; 92(11):1198-1203. PubMed ID: 28815695
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
12. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction.
Väkevä A; Laurila P; Meri S
Lab Invest; 1992 Nov; 67(5):608-16. PubMed ID: 1279272
[TBL] [Abstract][Full Text] [Related]
13. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
14. The cellular and molecular mechanisms of diabetic complications.
King GL; Brownlee M
Endocrinol Metab Clin North Am; 1996 Jun; 25(2):255-70. PubMed ID: 8799700
[TBL] [Abstract][Full Text] [Related]
15. Cloning of the sixth complement component and, spatial and temporal expression profile of MAC structural and regulatory genes in chicken.
Mikrou A; Zarkadis IK
Dev Comp Immunol; 2010 May; 34(5):485-90. PubMed ID: 20067805
[TBL] [Abstract][Full Text] [Related]
16. Complement activation at the motor end-plates in amyotrophic lateral sclerosis.
Bahia El Idrissi N; Bosch S; Ramaglia V; Aronica E; Baas F; Troost D
J Neuroinflammation; 2016 Apr; 13(1):72. PubMed ID: 27056040
[TBL] [Abstract][Full Text] [Related]
17. The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events.
Krus U; King BC; Nagaraj V; Gandasi NR; Sjölander J; Buda P; Garcia-Vaz E; Gomez MF; Ottosson-Laakso E; Storm P; Fex M; Vikman P; Zhang E; Barg S; Blom AM; Renström E
Cell Metab; 2014 May; 19(5):883-90. PubMed ID: 24726385
[TBL] [Abstract][Full Text] [Related]
18. Protection of gingival epithelium against complement-mediated damage by strong expression of the membrane attack complex inhibitor protectin (CD59).
Rautemaa R; Meri S
J Dent Res; 1996 Jan; 75(1):568-74. PubMed ID: 8655761
[TBL] [Abstract][Full Text] [Related]
19. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Morgan BP; Christadoss P
J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus X protein activates CD59 involving DNA binding and let-7i in protection of hepatoma and hepatic cells from complement attack.
Shan C; Zhang S; Cui W; You X; Kong G; Du Y; Qiu L; Ye L; Zhang X
Carcinogenesis; 2011 Aug; 32(8):1190-7. PubMed ID: 21665888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
